Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD
Cancer Cell · 2024-08 · 42 (8) · 1450-1466.e11
DOI: 10.1016/j.ccell.2024.07.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2024-08. Verfasst von Mayra Shanley und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA. Hauptthemen laut MEDLINE: Killer Cells, Natural, Glioblastoma, Interleukins, CCAAT-Enhancer-Binding Protein-delta. Die Arbeit wurde bisher 105-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Glioblastoma (GBM) is an aggressive brain cancer with limited therapeutic options. Natural killer (NK) cells are innate immune cells with strong anti-tumor activity and may offer a promising treatment strategy for GBM. We compared the anti-GBM activity of NK cells engineered to express interleukin (IL)-15 or IL-21. Using multiple in vivo models, IL-21 NK cells were superior to IL-15 NK cells both in terms of safety and long-term anti-tumor activity, with locoregionally administered IL-15 NK cells proving toxic and ineffective at tumor control. IL-21 NK cells displayed a unique chromatin accessibility signature, with CCAAT/enhancer-binding proteins (C/EBP), especially CEBPD, serving as key transcription factors regulating their enhanced function. Deletion of CEBPD resulted in loss of IL-21 NK cell potency while its overexpression increased NK cell long-term cytotoxicity and metabolic fitness. These results suggest that IL-21, through C/EBP transcription factors, drives epigenetic reprogramming of NK cells, enhancing their anti-tumor efficacy against GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
- Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
- Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
- Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
- Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.
Förderung
- NCI NIH HHS
- NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Shanley, M., Daher, M., Dou, J., Li, S., Basar, R., Rafei, H., Dede, M., Gumin, J., Pantaleόn Garcίa, J., Nunez Cortes, A. K., He, S., Jones, C. M., Acharya, S., Fowlkes, N. W., Xiong, D., Singh, S., Shaim, H., Hicks, S. C., Liu, B., …, & Rezvani, K. (2024). Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer Cell, 42(8), 1450-1466.e11. https://doi.org/10.1016/j.ccell.2024.07.007
Vancouver
Shanley M, Daher M, Dou J, Li S, Basar R, Rafei H, et al. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer Cell. 2024;42(8):1450-1466.e11. doi:10.1016/j.ccell.2024.07.007
BibTeX
@article{Shanley2024,
author = {Shanley, Mayra and Daher, May and Dou, Jinzhuang and Li, Sufang and Basar, Rafet and Rafei, Hind and Dede, Merve and Gumin, Joy and Pantaleόn Garcίa, Jezreel and Nunez Cortes, Ana Karen and He, Shan and Jones, Corry M and Acharya, Sunil and Fowlkes, Natalie W and Xiong, Donghai and Singh, Sanjay and Shaim, Hila and Hicks, Samantha Claire and Liu, Bin and Jain, Abhinav and Zaman, Mohammad Fayyad and Miao, Qi and Li, Ye and Uprety, Nadima and Liu, Enli and Muniz-Feliciano, Luis and Deyter, Gary M and Mohanty, Vakul and Zhang, Patrick and Evans, Scott E and Shpall, Elizabeth J and Lang, Frederick F and Chen, Ken and Rezvani, Katayoun},
title = {Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD},
journal = {Cancer Cell},
year = {2024},
volume = {42},
number = {8},
pages = {1450--1466.e11},
doi = {10.1016/j.ccell.2024.07.007}
}
EUVIMED